IRIS Accounts Production v26.1.10.61 09853556 Board of Directors 1.12.24 30.11.25 30.11.25 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh098535562024-11-30098535562025-11-30098535562024-12-012025-11-30098535562023-11-30098535562023-12-012024-11-30098535562024-11-3009853556ns15:EnglandWales2024-12-012025-11-3009853556ns14:PoundSterling2024-12-012025-11-3009853556ns10:Director12024-12-012025-11-3009853556ns10:PrivateLimitedCompanyLtd2024-12-012025-11-3009853556ns10:SmallEntities2024-12-012025-11-3009853556ns10:AuditExempt-NoAccountantsReport2024-12-012025-11-3009853556ns10:SmallCompaniesRegimeForDirectorsReport2024-12-012025-11-3009853556ns10:SmallCompaniesRegimeForAccounts2024-12-012025-11-3009853556ns10:FullAccounts2024-12-012025-11-3009853556ns10:Director22024-12-012025-11-3009853556ns10:RegisteredOffice2024-12-012025-11-3009853556ns5:CurrentFinancialInstruments2025-11-3009853556ns5:CurrentFinancialInstruments2024-11-3009853556ns5:Non-currentFinancialInstruments2025-11-3009853556ns5:Non-currentFinancialInstruments2024-11-3009853556ns5:ShareCapital2025-11-3009853556ns5:ShareCapital2024-11-3009853556ns5:RetainedEarningsAccumulatedLosses2025-11-3009853556ns5:RetainedEarningsAccumulatedLosses2024-11-3009853556ns5:PlantMachinery2024-12-012025-11-3009853556ns5:PlantMachinery2024-11-3009853556ns5:PlantMachinery2025-11-3009853556ns5:PlantMachinery2024-11-3009853556ns5:WithinOneYearns5:CurrentFinancialInstruments2025-11-3009853556ns5:WithinOneYearns5:CurrentFinancialInstruments2024-11-3009853556ns5:Secured2025-11-3009853556ns5:Secured2024-11-30
REGISTERED NUMBER: 09853556 (England and Wales)


















FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 NOVEMBER 2025

FOR

GSK DEVELOPMENT SOLUTIONS LTD

GSK DEVELOPMENT SOLUTIONS LTD (REGISTERED NUMBER: 09853556)

CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2025










Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


GSK DEVELOPMENT SOLUTIONS LTD

COMPANY INFORMATION
FOR THE YEAR ENDED 30 NOVEMBER 2025







DIRECTORS: H E Coleman
G S Kedgley





REGISTERED OFFICE: 31a Kenilworth Road
Leamington Spa
CV32 6JG





REGISTERED NUMBER: 09853556 (England and Wales)





ACCOUNTANTS: TGFP
Chartered Accountants
Fulford House
Newbold Terrace
Leamington Spa
Warwickshire
CV32 4EA

GSK DEVELOPMENT SOLUTIONS LTD (REGISTERED NUMBER: 09853556)

BALANCE SHEET
30 NOVEMBER 2025

2025 2024
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 6,867 400,312

CURRENT ASSETS
Stocks 5,284,000 3,455,045
Debtors 5 61,497 17,717
Cash at bank 215,094 47,779
5,560,591 3,520,541
CREDITORS
Amounts falling due within one year 6 2,769,216 1,354,077
NET CURRENT ASSETS 2,791,375 2,166,464
TOTAL ASSETS LESS CURRENT
LIABILITIES

2,798,242

2,566,776

CREDITORS
Amounts falling due after more than one
year

7

(2,100,329

)

(1,872,046

)

PROVISIONS FOR LIABILITIES - (25,528 )
NET ASSETS 697,913 669,202

CAPITAL AND RESERVES
Called up and paid share capital 1 1
Retained earnings 697,912 669,201
697,913 669,202

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 November 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 November 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

GSK DEVELOPMENT SOLUTIONS LTD (REGISTERED NUMBER: 09853556)

BALANCE SHEET - continued
30 NOVEMBER 2025


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 15 July 2026 and were signed on its behalf by:





G S Kedgley - Director


GSK DEVELOPMENT SOLUTIONS LTD (REGISTERED NUMBER: 09853556)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2025


1. STATUTORY INFORMATION

GSK Development Solutions Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery etc - 25% on reducing balance and 15% on reducing balance

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Financial instruments
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


GSK DEVELOPMENT SOLUTIONS LTD (REGISTERED NUMBER: 09853556)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 NOVEMBER 2025


2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 3 (2024 - 3 ) .

4. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
At 1 December 2024 491,581
Additions 757
Disposals (459,272 )
At 30 November 2025 33,066
DEPRECIATION
At 1 December 2024 91,269
Charge for year 39,357
Eliminated on disposal (104,427 )
At 30 November 2025 26,199
NET BOOK VALUE
At 30 November 2025 6,867
At 30 November 2024 400,312

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
£    £   
Other debtors 61,497 17,717

GSK DEVELOPMENT SOLUTIONS LTD (REGISTERED NUMBER: 09853556)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 NOVEMBER 2025


6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
£    £   
Bank loans and overdrafts 10,461 10,461
Hire purchase contracts - 22,285
Taxation and social security 3,898 4,417
Other creditors 2,754,857 1,316,914
2,769,216 1,354,077

7. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
2025 2024
£    £   
Bank loans 2,100,329 1,749,495
Hire purchase contracts - 122,551
2,100,329 1,872,046

Amounts falling due in more than five years:

Repayable by instalments
Bank loans more 5 yr by instal 2,099,868 507,984

8. SECURED DEBTS

The following secured debts are included within creditors:

2025 2024
£    £   
Bank loans 2,110,790 -
Other loans 1,861,496 -
3,972,286 -

Monmouth Building Society have a fixed and floating charge over 4 Victoria Court. This charge contains a negative pledge. They also have the same charge applied to Old Mill House and the land and building on the south side of Cross Street.

Reay Investment Limited has a fixed charge over the freehold land on the north-east side of Broadway Road. This charge contains a negative pledge.